Advertisement
Melody Petersen

Melody Petersen covers biotechnology for the Los Angeles Times. Previously, she wrote about the pharmaceutical industry for the New York Times. She won a Loeb award for reporting about a power company at the San Jose Mercury News. She has also written for the Orange County Register and the Philadelphia Inquirer. She’s the author of Our Daily Meds, a book about the drug industry. She’s a former certified public accountant and grew up on an Iowa farm.
Pacientes demandan a la farmacéutica Gilead por haber retrasado intencionalmente una medicina más segura contra el VIH

La demanda señala que los pacientes con VIH sufrieron hasta una década de "toxicidad acumulada en riñones y huesos".

Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine

Two Southern California men filed suit against Gilead Sciences on Tuesday, saying they were harmed when the drug company intentionally delayed development of a safer alternative to a crucial HIV medicine so that it could continue to profit from its monopoly.

Advertisement
Advertisement